LLY

1,015.16

+3.18%↑

JNJ

229.65

+0.21%↑

ABBV

214.18

+2.75%↑

UNH

390.74

+0.12%↑

AZN

184.55

+0.28%↑

LLY

1,015.16

+3.18%↑

JNJ

229.65

+0.21%↑

ABBV

214.18

+2.75%↑

UNH

390.74

+0.12%↑

AZN

184.55

+0.28%↑

LLY

1,015.16

+3.18%↑

JNJ

229.65

+0.21%↑

ABBV

214.18

+2.75%↑

UNH

390.74

+0.12%↑

AZN

184.55

+0.28%↑

LLY

1,015.16

+3.18%↑

JNJ

229.65

+0.21%↑

ABBV

214.18

+2.75%↑

UNH

390.74

+0.12%↑

AZN

184.55

+0.28%↑

LLY

1,015.16

+3.18%↑

JNJ

229.65

+0.21%↑

ABBV

214.18

+2.75%↑

UNH

390.74

+0.12%↑

AZN

184.55

+0.28%↑

Inicio・Lista de Acciones・Kura Oncology Inc

Kura Oncology Inc

Abierto

SectorSanidad

9.09 -0.98

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

8.98

Máximo

9.23

Métricas clave
By Trading Economics
Ingresos	-6.9M -81M
Ventas	-3.4M 17M
Margen de beneficios	-467.23
Empleados	260
EBITDA	-12M -86M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+205.1% upside

Dividendos
By Dow Jones
Próximas Ganancias	6 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	89M 844M
Apertura anterior	10.07
Cierre anterior	9.09

Noticias sobre sentimiento de mercado

By Acuity

55%

45%

266 / 345 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

5.575 / 6.6 Soporte y Resistencia

Kura Oncology Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

18 may 2026, 23:10 UTC

Acciones populares

Stocks to Watch: Agilysys, XP

18 may 2026, 18:44 UTC

Principales Movimientos del Mercado

Claritev Shares Recover After Comments About DOJ

18 may 2026, 23:55 UTC

Ganancias

Review & Preview: Earnings' Last Gasp -- Barrons.com

18 may 2026, 23:47 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

18 may 2026, 23:47 UTC

Charlas de Mercado

Nikkei May Rise on Hopes for U.S.-Iran Deal -- Market Talk

18 may 2026, 23:37 UTC

Charlas de Mercado

Gold Rises Amid Hopes for U.S.-Iran Peace Deal -- Market Talk

18 may 2026, 22:31 UTC

Adquisiciones, fusiones, absorciones

Lens Technology Ju Teng International Shares to Resume Trading on Hong Kong Exchange on May 19

18 may 2026, 22:30 UTC

Adquisiciones, fusiones, absorciones

Lens Technology: Acquisition of Remaining Ju Teng International Shares to Cost HK$1.91B

18 may 2026, 22:30 UTC

Adquisiciones, fusiones, absorciones

Lens Technology to Make Offer for Remainder Shares of Ju Teng International Only After Completion of Stake Purchase

18 may 2026, 22:25 UTC

Adquisiciones, fusiones, absorciones

Lens Technology to Acquire 333.71M Ju Teng International Shares for HK$2.20 Each

18 may 2026, 22:24 UTC

Adquisiciones, fusiones, absorciones

Lens Technology to Acquire 27.81% Stake in Ju Teng International for HK$734.17M

18 may 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

18 may 2026, 20:50 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Financial Services Roundup: Market Talk

18 may 2026, 20:25 UTC

Ganancias

Correct: XP 1Q Total Client Assets BRL1.53T

18 may 2026, 20:23 UTC

Ganancias

XP 1Q Total Client Assets BRL1.53B

18 may 2026, 20:19 UTC

Ganancias

XP 1Q Adj EPS BRL2.49 >XP

18 may 2026, 20:19 UTC

Ganancias

XP 1Q Rev BRL4.73B >XP

18 may 2026, 19:10 UTC

Charlas de Mercado

Oil Presses Higher With No Hormuz Reopening in Sight -- Market Talk

18 may 2026, 19:00 UTC

Ganancias

5 Stocks with 5% Yields and Market-Beating Returns -- Barrons.com

18 may 2026, 18:52 UTC

Charlas de Mercado

U.S. Natural Gas Futures Gain As Weather Heats Up -- Market Talk

18 may 2026, 18:17 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

NextEra's Dominion Acquisition Unlikely to Spur Wider Utility Consolidation -- Market Talk

18 may 2026, 17:22 UTC

Charlas de Mercado

Tokenized Assets Expected to be Over $1T By 2030 -- Market Talk

18 may 2026, 16:57 UTC

Adquisiciones, fusiones, absorciones

The Long Regulatory Road Ahead for the NextEra-Dominion Deal -- Barrons.com

18 may 2026, 16:57 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

18 may 2026, 16:57 UTC

Charlas de Mercado

Commodities Higher as Traders Want Physical Assets -- Market Talk

18 may 2026, 16:54 UTC

Adquisiciones, fusiones, absorciones

Vinci Doesn't Set Out Financial Details of Deal

18 may 2026, 16:50 UTC

Adquisiciones, fusiones, absorciones

Vinci: Acquisition of New Brunswick-Based Group Stregthens Presence in Eastern Canada

18 may 2026, 16:49 UTC

Adquisiciones, fusiones, absorciones

Vinci: Modern Group is Roadwork, Civil Engineering Specialist

18 may 2026, 16:49 UTC

Adquisiciones, fusiones, absorciones

Vinci: Modern Group Made Revenue of Around 50 Mln Euros Last Year

18 may 2026, 16:48 UTC

Adquisiciones, fusiones, absorciones

Vinci Buys Canada's Modern Group of Companies

Comparación entre iguales

Cambio de precio

Kura Oncology Inc previsión

Precio Objetivo

By TipRanks

205.1% repunte

Estimación a 12 Meses

Media 28.13 USD 205.1%

Máximo 40 USD

Mínimo 15 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Kura Oncology Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

10 ratings

Comprar

Mantener

Vender

De acuerdo con 10 analistas que ofrecen calificaciones bursátiles a para Kura Oncology Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

5.575 / 6.6Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentimiento

By Acuity

266 / 345 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.